Antonino Missineo
IRBM Science Park · 23 works · 436 citations · h-index 11
Top works
- Toll-Like Receptors (TLRs) in Innate Immune Defense Against Staphylococcus Aureus
- IsdC from Staphylococcus lugdunensis Induces Biofilm Formation under Low-Iron Growth Conditions
- Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening
- Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)
- NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model
- Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors
- Molecular Characterization of the Multiple Interactions of SpsD, a Surface Protein from Staphylococcus pseudintermedius, with Host Extracellular Matrix Proteins
- Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: An investigation on lipidated GLP-1 analogs
- High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting
- Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction
- Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme
- SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease
- An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models
- A21 Development of an Nrf2-KEAP1 protein-protein disruptor for proof of concept
- Identification by High-Throughput Screening of Pseudomonas Acyl–Coenzyme A Synthetase Inhibitors
- Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL
- Development of a Broadly Applicable Assay for Measurement of Glycan-Directed Enzymatic Activity
- Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL
- Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor
- Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers